U.S. Supreme Court Rejects CareDxA’s Appeal in Natera, Inc. (NTRA) False-advertising Dispute
The U.S. Supreme Court declined to hear CareDx's appeal in its false-advertising dispute with Natera, effectively leaving intact a lower-court ruling that favored Natera's marketing claims for its Prospera kidney transplant test. This removes a key legal overhang for NTRA and could strengthen its competitive positioning in the transplant diagnostics market against CareDx.
What happened
The U.S. Supreme Court declined to hear CareDx's appeal in its false-advertising dispute with Natera, effectively leaving intact a lower-court ruling that favored Natera's marketing claims for its Prospera kidney transplant test.
The read · Jun 28
With the Supreme Court closing Natera's last legal risk on its Prospera marketing claims, the question is whether NTRA's cleared competitive runway is already priced into its growth multiple or represents a fresh catalyst — while CDNA faces an incremental headwind.
Wrong if
NTRA is not yet profitable (-9% net margin, -$1.52 EPS), and its revenue growth is already well-known and reflected in a premium multiple — any macro derisking or miss on the next earnings print could overwhelm the legal catalyst. CareDx could also respond aggressively with new clinical data or pricing that blunts Prospera share gains.
CoverageSource: Yahoo Finance · Published here SUN, JUN 28 · 3:58 PM ET · the only report in this recordHow this is decided →
The chart · NTRATradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
The U.S. Supreme Court has rejected CareDx's petition for certiorari in its false-advertising lawsuit against Natera, meaning the lower-court outcome favorable to Natera stands as the final word. The dispute centered on marketing claims Natera made about its Prospera cell-free DNA kidney transplant rejection test, which CareDx alleged were misleading relative to its own competing AlloSure product. The Supreme Court's refusal to hear the appeal closes the litigation chapter without further risk to Natera's commercial practices.
Natera is already on a strong revenue trajectory — $2.3B in FY2025 with 35.9% year-over-year growth — though the company still runs a -9.0% net margin and a -$1.52 diluted EPS, meaning it is not yet profitable. The legal win matters commercially because it frees Natera to continue its current marketing approach for Prospera without court-imposed restrictions, potentially accelerating market share gains in transplant monitoring.
The second-order setup is whether this legal clarity translates into accelerating Prospera adoption at the expense of CareDx's AlloSure, and whether Natera can convert its revenue momentum into profitability faster with a cleared competitive runway. CareDx (CDNA) faces the inverse dynamic — not only did its legal strategy fail, but Natera's marketing claims now carry the implicit endorsement of surviving judicial scrutiny.
What to watch: Natera's next earnings print for Prospera volume data and any guidance revision, and whether CareDx responds with pricing or clinical data to reassert its position. The residual risk for NTRA is that the growth story is already well-known given its strong revenue print, so the legal win may already be partially priced in.
The read, in fullWhy it matters
The Supreme Court denial removes the last legal risk to Natera's Prospera marketing strategy, cementing competitive positioning against CareDx. NTRA's 35.9% revenue growth shows the commercial engine is firing, and the legal clarity could accelerate Prospera adoption. Pairing long NTRA against short CDNA isolates the relative competitive dynamic rather than taking outright directional risk on an unprofitable grower.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written · closes shown from JUN 29 on
Next · what would move this
4-6 weeks / into next earnings print. Follow to be told when one lands.
Since this story · named here, equal weight · 1D EOD+47.1%
JUN 29 · first close after publicationSEP 4
Price context does not establish that the story caused the move.
▲ The case it holds
The Supreme Court denial validates Natera's Prospera marketing claims and removes litigation overhang, potentially accelerating commercial adoption of Prospera at a time when NTRA is already growing revenues 35.9% YoY — a combination that could prompt consensus estimate upgrades.
▼ The case it breaks
NTRA still runs a -9.0% net margin with no clear profitability timeline, and the legal win may be fully priced into a premium growth multiple, leaving the stock vulnerable to any slowdown in the revenue trajectory or a broader derating of unprofitable high-growth healthcare names.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →